LAUSR

Clinicians should have a low threshold for screening for G6PD deficiency in patients with COVID-19 in order to provide effective treatment and avoid complications. B Discussion: b To our knowledge, this is the first report of severe rhabdomyolysis and renal failure in the setting of G6PD deficiency and COVID-19 disease. B Introduction: b Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common enzyme defects worldwide. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)